<DOC>
	<DOCNO>NCT01168908</DOCNO>
	<brief_summary>This study , support Charley 's Fund , Inc. , do determine drug RevatioÂ® ( also know Sildenafil ) , compare placebo ( inactive substance look like study drug , contain medication ) , improve heart function people Duchenne Muscular Dystrophy Becker Muscular Dystrophy ( DBMD ) . In people DBMD , dystrophin present lack heart muscle . This associated abnormality enzyme call `` neuronal nitric oxide synthase '' nNOS , lead decrease `` cyclic GMP , '' necessary proper function muscle . Revatio block enzyme call phosphodiesterase 5 ( PDE5 ) , help restore normal amount cyclic GMP . The purpose research determine Revatio safe people DBMD improve heart function . Hypothesis : PDE5 inhibition , use Revatio , improve cardiac function patient DBMD .</brief_summary>
	<brief_title>Revatio Heart Disease Duchenne Muscular Dystrophy Becker Muscular Dystrophy</brief_title>
	<detailed_description>This clinical trial focus cardiovascular disease due dystrophin deficiency . Dystrophin normally localize muscle cell membrane interacts complex protein include neuronal nitric oxide synthase ( nNOS ) . DMD gene mutation lead loss dystrophin mislocalization reduce activity nNOS , consequently reduce cyclic guanosine monophosphate ( cGMP ) activity downstream effector , protein kinase G. Our group others show inhibition phosphodiesterase 5 ( PDE5 ) lead favorable cardiac remodel improved vascular tone animal model heart failure . This phase 2 , randomize , double-blind , placebo-controlled single center study 6 month follow open-label period 6 month enrol subject receive Revatio ( PDE5 inhibitor ) . A single dose Revatio ( 20 mg three time daily ) test base safety efficacy dose treatment pulmonary hypertension . The primary endpoint change cardiac leave ventricular end-systolic volume ( LVESV ) determine cardiac MRI 6 month Revatio compare baseline . A 10 % change LVESV consider significant . This degree improvement generally observe cardiac therapy improve survival ACE inhibitor , beta blocker , cardiac resynchronization . The change baseline LVESV 6 month Revatio compare change LVESV 6 month placebo . The study extend additional 6 month open-label Revatio provide data 6 month versus 12 month Revatio treatment . Additional secondary endpoint include difference systolic diastolic LV function MRI , differences LV mass fibrosis MRI , brachial flow-mediated vasodilation ( peripheral endothelial function ) , target exploratory assessment difference skeletal muscle function use force vital capacity ( FVC ) pincher grip test . Safety assess difference frequency grade adverse event The study take place Kennedy Krieger Institute/Johns Hopkins Medical Institutions Baltimore , MD . The trial require out-patient visit 12-month period . Travel fund , grant Ryan 's Quest , available .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>1 . DBMD determine either skeletal muscle biopsy demonstrate absence lack dystrophin , and/or genetic test show mutation dystrophin gene predictive DBMD , well consistent physical examination 2 . Male gender 3 . Age great equal 18 year 4 . Cardiac dysfunction ejection fraction less equal 50 % determined echocardiogram , cardiac MRI , multigated acquisition ( MUGA ) scan 5 . On stable dose ACEinhibitor angiotensin receptor blocker ( ARB ) least 3 month ; betaadrenergic receptor blocker glucocorticosteroids require use , stable dose least 3 month require . 6 . Ability subject legal guardian provide inform consent 7 . Ability adhere study followup 8 . Willingness abstain food alcohol 8 hour prior FMD 1 . Use nitrate alphaadrenergic receptor blocker 2 . Known intolerance allergy sildenafil , history severe allergic anaphylactic reaction 3 . Any medical psychosocial condition , , view study investigator , make study participation inadvisable 4 . Known hereditary retinal disorder retinitis pigmentosa 5 . History priapism condition may predispose priapism sickle cell anemia , multiple myeloma , leukemia 6 . Bleeding disorder 7 . Active tobacco use 8 . Chronic atrial fibrillation frequent arrhythmia would result irregular pulse 9 . Factors would preclude obtain MRI study ( e.g . implantable pacemaker cardioverterdefibrillator ; body habitus fit scanner ) 10 . Systolic blood pressure ( SBP ) less 85 mmHg baseline evaluation 11 . Chronic kidney disease stag 4 5 : GFR &lt; 30 mL/min/1.73 m2 determine serum cystatin C level equation eGFRcys = 76.7 x ( serum cystatin C1.18 ) 12 . Current use sildenafil .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Clinical trial</keyword>
	<keyword>Revatio</keyword>
	<keyword>Sildenafil</keyword>
	<keyword>Muscular Dystrophy</keyword>
	<keyword>Duchenne</keyword>
	<keyword>Becker</keyword>
	<keyword>Adult</keyword>
	<keyword>Adolescent</keyword>
</DOC>